Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGSAVI in Essential Hypertension Inadequately Controlled With AGLS
NCT05503953Phase 3Completed
- Sponsor
- Ahn-Gook Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of s-amlodipine + valsartan + indapamide in essential hypertension, sponsored by Ahn-Gook Pharmaceutical Co., Ltd.. Started Sep 2022; status: completed.
02
Drugs
s-amlodipine + valsartan + indapamide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05503953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503953.